✦ LIBER ✦

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

✍ Scribed by Gianni, Luca; Eiermann, Wolfgang; Semiglazov, Vladimir; Lluch, Ana; Tjulandin, Sergei; Zambetti, Milvia; Moliterni, Angela; Vazquez, Federico; Byakhov, Mikhail J; Lichinitser, Mikhail; Climent, Miguel Angel; Ciruelos, Eva; Ojeda, Belen; Mansutti, Mauro; Bozhok, Alla; Magazzù, Domenico; Heinzmann, Dominik; Steinseifer, Jutta; Valagussa, Pinuccia; Baselga, Jose

Book ID: 121800489
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 294 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70080-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant chemotherapy with trastuzuma

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

✍ Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 124 KB

2-year follow-up of trastuzumab after ad

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

✍ Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyerei 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 183 KB

Treatment with trastuzumab for 1 year af

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

✍ Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbaue 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 322 KB

Neoadjuvant carboplatin in patients with

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

✍ von Minckwitz, Gunter; Schneeweiss, Andreas; Loibl, Sibylle; Salat, Christoph; D 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 459 KB

Hormone-receptor status and likelihood o

Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

✍ W. Eiermann; J. Baselga; V. Semiglazov; M. Byakhov; E. Ciruelos; B. Ojeda; A. Fe 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Efficacy and safety of neoadjuvant pertu

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

✍ Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; M 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 217 KB